CO2020001792A2 - Combinaciones farmacéuticas - Google Patents

Combinaciones farmacéuticas

Info

Publication number
CO2020001792A2
CO2020001792A2 CONC2020/0001792A CO2020001792A CO2020001792A2 CO 2020001792 A2 CO2020001792 A2 CO 2020001792A2 CO 2020001792 A CO2020001792 A CO 2020001792A CO 2020001792 A2 CO2020001792 A2 CO 2020001792A2
Authority
CO
Colombia
Prior art keywords
bst1
pharmaceutical combinations
adp
activity
ribosyl cyclase
Prior art date
Application number
CONC2020/0001792A
Other languages
English (en)
Inventor
Monica Binaschi
Cecilia Simonelli
Andrea Pellacani
Daniela Bellarosa
Corrado Carrisi
Original Assignee
Berlin Chemie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berlin Chemie Ag filed Critical Berlin Chemie Ag
Publication of CO2020001792A2 publication Critical patent/CO2020001792A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La invención se refiere a combinaciones farmacéuticas que comprenden anticuerpos contra BST1 (ADP–ribosil ciclasa 2) junto con un análogo de citidina o una de sus sales farmacéuticamente aceptables, y métodos para el tratamiento de enfermedades tales como cánceres mediados por la expresión / actividad de BST1 (ADP–ribosil ciclasa 2) y/o asociados con la expresión / actividad anormal de BST1.
CONC2020/0001792A 2017-07-21 2020-02-18 Combinaciones farmacéuticas CO2020001792A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1711785.4A GB201711785D0 (en) 2017-07-21 2017-07-21 Antibodies
PCT/EP2018/069768 WO2019016371A1 (en) 2017-07-21 2018-07-20 PHARMACEUTICAL ASSOCIATIONS COMPRISING ANTI-BST-1 ANTIBODY AND A CYTIDINE ANALOG

Publications (1)

Publication Number Publication Date
CO2020001792A2 true CO2020001792A2 (es) 2020-07-31

Family

ID=59771583

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0001792A CO2020001792A2 (es) 2017-07-21 2020-02-18 Combinaciones farmacéuticas

Country Status (22)

Country Link
US (1) US20200231694A1 (es)
EP (1) EP3655033A1 (es)
JP (1) JP2020527594A (es)
KR (1) KR20200032162A (es)
CN (1) CN111132697A (es)
AR (1) AR112460A1 (es)
AU (1) AU2018303241A1 (es)
BR (1) BR112020001320A2 (es)
CA (1) CA3070264A1 (es)
CL (1) CL2020000175A1 (es)
CO (1) CO2020001792A2 (es)
EA (1) EA202090333A1 (es)
GB (1) GB201711785D0 (es)
IL (1) IL272096A (es)
MA (1) MA49627A (es)
MX (1) MX2020000752A (es)
PH (1) PH12020550024A1 (es)
SG (1) SG11202000390TA (es)
TW (1) TW201907952A (es)
UY (1) UY37815A (es)
WO (1) WO2019016371A1 (es)
ZA (1) ZA202000881B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201809746D0 (en) * 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004063494A1 (de) * 2004-12-23 2006-07-13 Tegenero Ag Antikörper
KR102058185B1 (ko) * 2011-06-28 2019-12-20 옥스포드 바이오테라퓨틱스 리미티드 Adp-리보실 시클라제 2에 대한 항체
GB201806084D0 (en) * 2018-04-13 2018-05-30 Berlin Chemie Ag Antibodies
CN118178645A (zh) * 2019-10-18 2024-06-14 四十七公司 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法

Also Published As

Publication number Publication date
MA49627A (fr) 2020-05-27
CA3070264A1 (en) 2019-01-24
MX2020000752A (es) 2020-08-17
EP3655033A1 (en) 2020-05-27
GB201711785D0 (en) 2017-09-06
JP2020527594A (ja) 2020-09-10
CL2020000175A1 (es) 2020-06-12
AU2018303241A1 (en) 2020-02-20
UY37815A (es) 2019-02-28
SG11202000390TA (en) 2020-02-27
IL272096A (en) 2020-03-31
TW201907952A (zh) 2019-03-01
KR20200032162A (ko) 2020-03-25
AR112460A1 (es) 2019-10-30
US20200231694A1 (en) 2020-07-23
CN111132697A (zh) 2020-05-08
ZA202000881B (en) 2021-08-25
EA202090333A1 (ru) 2020-05-06
WO2019016371A1 (en) 2019-01-24
PH12020550024A1 (en) 2021-02-15
BR112020001320A2 (pt) 2020-08-11

Similar Documents

Publication Publication Date Title
BR112017012377A2 (pt) conjugados anticorpo-fármaco com inibidores de bcl-xl permeáveis à célula
BR112016029041A2 (pt) terapia de combinação com inibidores de glutaminase
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
CO2021006075A2 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
CO2018008846A2 (es) Derivados de carboxamida útiles como inhibidores de rsk
CL2020001742A1 (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades
BR112018072545A2 (pt) inibidores da arginase e suas aplicações terapêuticas
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
GT201600269A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
WO2015117010A3 (en) Bag3 as a target for therapy of heart failure
CO2019002523A2 (es) Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica
BR112017000730B8 (pt) Derivados de pirrolidinona como inibidores de metap-2, e medicamentos
SV2016005313A (es) Derivados de carboxamida
SV2017005354A (es) Derivados de quinolizinona como inhibidores de pi3k
ECSP21071644A (es) Compuestos macrocíclicos como agonistas de sting
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
ECSP21015491A (es) Administración prolongada de lasmiditan por la noche para la prevención de la migraña
CL2020002038A1 (es) Oligonucleótidos para modular la expresión de tmem106b.
CL2020001093A1 (es) Proceso para preparar el benzotiofen-2-il boronato.
CO2020001792A2 (es) Combinaciones farmacéuticas
CL2018003338A1 (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
PE20200749A1 (es) Moduladores de la expresion de enac
CO2020001375A2 (es) Derivado de adamantilmetilamina y uso del mismo como producto farmacéutico
CO2020000617A2 (es) Novedosos compuestos que activan la ruta nrf2
CL2017002351A1 (es) Agente terapéutico para disfunción del lóbulo frontal